Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report

Crizotinib is one of the molecularly-targeted agents targeted against anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). Although its effects appear to be promising, crizotinib may cause adverse effects in patients with ALK-rearranged NSCLC. Hepatic laboratory abnormalit...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Clin Oncol
Asıl Yazarlar: Yasuda, Yuto, Nishikawa, Yasuyo, Sakamori, Yuichi, Terao, Makoto, Hashimoto, Kentaro, Funazo, Tomoko, Nomizo, Takashi, Tsuji, Takahiro, Yoshida, Hironori, Nagai, Hiroki, Ozasa, Hiroaki, Hirai, Toyohiro, Kim, Young Hak
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: D.A. Spandidos 2017
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5532690/
https://ncbi.nlm.nih.gov/pubmed/28781805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1310
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller